KMT2A and leukemia: To determine whether the O-glycochain is necessary for binding of each mAb, we stained MLL/AF9 leukemia cells or M1 leukemia cells treated with benzyl-GalNac, an O-glycosylation inhibitor, with each mAb and then analyzed the stained cells by FACS.